Arkolith/Insider Trading/RPRX/Form 4

Hite Christopher

EVP & Vice ChairmanRoyalty Pharma plc (RPRX) · full profile →Form 4 · filed Nov 7, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 5, 2025Grant(A)6K—$0659K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001814238-25-000003) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML